Pharmacologic treatment of gastroparesis: What is (still) on the horizon?

Curr Opin Pharmacol. 2023 Aug 26;72:102395. doi: 10.1016/j.coph.2023.102395. Online ahead of print.ABSTRACTGastroparesis is a neuromuscular disorder of the upper gastrointestinal tract. Patients typically complain about early satiety, postprandial fullness, nausea and vomiting. Etiology is multifactorial. Treatment strategies include nutritional support, pharmacologic agents or surgery for refractory cases. Metoclopramide is the first and only FDA approved pharmacologic agent for (diabetic) Gastroparesis. A couple of compounds are currently in clinical testing. Some beacons of hope have failed recently, however. Here we present an update on possible future treatment options.PMID:37639905 | DOI:10.1016/j.coph.2023.102395
Source: Current Opinion in Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research